Tag: FDA Watch List
-
Vascular Endothelial Growth Factor (VEGF) Inhibitors: Increased Risk Of Aneurysm And Artery Dissection
New Warnings Added To Drug Labels For All VEGF Inhibitors By UK's MHRA Already; FDA Is Evaluating Need For Regulatory Action (Posted by Tom Lamb at DrugInjuryWatch.com) On July 31, 2020 the…
-
Actemra Side Effects: Pulmonary Hypertension, Interstitial Lung Disease, Pulmonary Alveolar Proteinosis
FDA Watch List Includes Actemra: Evaluating Regulatory Action Based On Possible Signs Of Serious Risk, New Safety Information (Posted by Tom Lamb at DrugInjuryWatch.com) In July 2018 the FDA issued this document,…
-
Sanofi Heart Medication Multaq Has Constantly Been On FDA’s Radar During 2010 And 2011
Liver Failure, Renal Impairment, And Cardiovascular Problems Cited As Potential Signals Of Risk Involving Multaq (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: Health Canada announced on July 21, 2011 that it is reviewing…